News
1d
GlobalData on MSNNovo Nordisk defeated in Wegovy patent dispute by ViatrisThe Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...
Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...
The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...
7d
Zacks.com on MSNCan Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...
Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.
Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results